Pharmacology
Nursing Clotting and Coagulation Quiz
Comprehensive Study Guide
UPDATE
Actual Questions & Verified Answers
with Detailed Clinical Rationales
Practice Questions with Rationales
Nursing Program
Pharmacology
✓ 100% Verified Answers
✓ Complete Rationales Included
Exam (elaborations)
Instant PDF Download • Ready for Study
,Pharmacology Nursing: Clotting and Coagulation Quiz 2026/2027 UPDATE
1. A patient receiving a continuous heparin infusion for a pulmonary embolism has a PTT of
110 seconds (control 25-35). What is the nurse’s priority action?
A. Increase the infusion rate as per protocol.
B. Stop the infusion and notify the healthcare provider.
C. Administer Vitamin K intramuscularly.
D. Document the finding as a therapeutic level.
Answer: B
Rationale: The therapeutic range for PTT is generally 1.5 to 2.5 times the control. 110
seconds is significantly above the therapeutic range, placing the patient at high risk for
bleeding. The infusion must be stopped immediately.
2. Which mechanism best describes the action of Heparin in the body?
A. Inhibits the synthesis of Vitamin K-dependent clotting factors.
B. Blocks ADP receptors on the platelet surface.
C. Binds to antithrombin III, inactivating thrombin and factor Xa.
D. Directly dissolves established fibrin clots.
Answer: C
, Rationale: Heparin works by binding to antithrombin III, which accelerates the
inactivation of thrombin and factor Xa, preventing the formation of fibrin.
3. A patient is diagnosed with Heparin-Induced Thrombocytopenia (HIT). Which medication is
the most appropriate alternative for anticoagulation?
A. Enoxaparin
B. Warfarin
C. Aspirin
D. Argatroban
Answer: D
Rationale: Argatroban is a direct thrombin inhibitor used as an alternative for patients
who develop HIT. LMWHs like Enoxaparin are contraindicated in HIT.
4. What is the specific reversal agent for Dabigatran (Pradaxa)?
A. Idarucizumab
B. Vitamin K
C. Protamine Sulfate
D. Andexanet Alfa
Answer: A
Rationale: Idarucizumab (Praxbind) is a monoclonal antibody fragment that specifically
binds to and reverses the effects of the direct thrombin inhibitor Dabigatran.
Nursing Clotting and Coagulation Quiz
Comprehensive Study Guide
UPDATE
Actual Questions & Verified Answers
with Detailed Clinical Rationales
Practice Questions with Rationales
Nursing Program
Pharmacology
✓ 100% Verified Answers
✓ Complete Rationales Included
Exam (elaborations)
Instant PDF Download • Ready for Study
,Pharmacology Nursing: Clotting and Coagulation Quiz 2026/2027 UPDATE
1. A patient receiving a continuous heparin infusion for a pulmonary embolism has a PTT of
110 seconds (control 25-35). What is the nurse’s priority action?
A. Increase the infusion rate as per protocol.
B. Stop the infusion and notify the healthcare provider.
C. Administer Vitamin K intramuscularly.
D. Document the finding as a therapeutic level.
Answer: B
Rationale: The therapeutic range for PTT is generally 1.5 to 2.5 times the control. 110
seconds is significantly above the therapeutic range, placing the patient at high risk for
bleeding. The infusion must be stopped immediately.
2. Which mechanism best describes the action of Heparin in the body?
A. Inhibits the synthesis of Vitamin K-dependent clotting factors.
B. Blocks ADP receptors on the platelet surface.
C. Binds to antithrombin III, inactivating thrombin and factor Xa.
D. Directly dissolves established fibrin clots.
Answer: C
, Rationale: Heparin works by binding to antithrombin III, which accelerates the
inactivation of thrombin and factor Xa, preventing the formation of fibrin.
3. A patient is diagnosed with Heparin-Induced Thrombocytopenia (HIT). Which medication is
the most appropriate alternative for anticoagulation?
A. Enoxaparin
B. Warfarin
C. Aspirin
D. Argatroban
Answer: D
Rationale: Argatroban is a direct thrombin inhibitor used as an alternative for patients
who develop HIT. LMWHs like Enoxaparin are contraindicated in HIT.
4. What is the specific reversal agent for Dabigatran (Pradaxa)?
A. Idarucizumab
B. Vitamin K
C. Protamine Sulfate
D. Andexanet Alfa
Answer: A
Rationale: Idarucizumab (Praxbind) is a monoclonal antibody fragment that specifically
binds to and reverses the effects of the direct thrombin inhibitor Dabigatran.
